Sector Alpha Week of 2026-09-11
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-11

Gem Aromatics Ltd

GEMAROMA
Chemicals - Organic

Gem Aromatics Ltd's price has outrun its earnings. −44.5% in a year against EPS −97.6% — the market is paying now for delivery later.

The sharpest disagreement: the price moved −44.5% in a year while annual EPS moved −97.6% — the difference is re-rating, and re-rating has to be repaid with earnings.

The price is in a downtrend (55 weeks in) while the P/E sits at the 65th percentile of its own 1-year range. Underneath, the last four quarters read deteriorating — profit −198.6% year on year, and 43% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.

Price
₹161
−44.5% 1Y
P/E
25.8×
65th pctile
of its own 1-year range
Revenue (Jun 26)
₹98.8 Cr
+12.8% YoY
Profit (Jun 26)
₹−7.9 Cr
−198.6% YoY
Operating margin
3.3%
−13.6 pp YoY
ROCE
3%
FY26
ROIC
0.7%
vs WACC 12.0% → −11.3 pp
Cash conversion
43%
of profit, last 3 FY
Unverified figures: Some figures on this page come from a second financial-data feed that could not be cross-checked against the primary source — the two do not share enough overlapping reported history to compare. They are drawn, because they are the only evidence there is, and every section carrying one is marked unverified.
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Gem Aromatics Ltd trades at ₹161, in a downtrend and 55 weeks into that stage. That is −14.3% against its own 200-day average. It sits at 18% of a 52-week range of ₹141 to ₹252. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (5 weeks and counting).

Today the stock is in a downtrend — week 55 of stage 4, confirmed. At ₹161 it trades −14.3% versus its 200-day average and sits at 18% of its 52-week range (₹141–₹252).

Sep 26: ₹161 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 1-year window.
−14.3% versus the 200-day line, week 55 of stage 4
Price50-day avg200-day avg
S4₹333₹281₹230₹179₹127₹161₹188Aug 25Dec 25Mar 26Jun 26Sep 26
S4₹333₹281₹230₹179₹127₹161₹188Aug 25Mar 26Sep 26
Beating or trailing, week by week since 2025 Each cell is one week from 2025 to now (58 weeks): the stock's trailing 13-week return minus the NIFTY 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the NIFTY 500 reading is not held.
trailing 13-week return vs the NIFTY 500
Aug 25Sep 26

Against the market, two honest reads. Cumulative: over the last 1.0 years the stock moved −42% while the NIFTY 500 moved +0% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (5 weeks and counting; last ahead the week of 2026-08-07) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Gem Aromatics Ltd trades at 25.8× P/E, mid-range by its own standards (65th percentile). Its long-run median P/E is 23.9×, measured across 0.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 25.8× is mid-range by its own standards (65th percentile), against a long-run median of 23.9× measured over 0.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 25.8× vs a 23.9× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly (right axis). 0.7-year window; loss-period spikes above 32× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
mid-range by its own standards (65th percentile)
P/EMedianEPS (TTM) (quarterly)
33.8×₹12.328.9×₹9.223.9×₹6.119.0×₹3.114.1×₹0.0×25.80×₹6Aug 25Oct 25Jan 26Mar 26May 26
33.8×₹12.328.9×₹9.223.9×₹6.119.0×₹3.114.1×₹0.0×25.80×₹6Aug 25Jan 26May 26
P/E
25.8×
65th percentile of 1y

🚨 Why the multiple sits where it does: over the past year annual EPS moved −97.6% against a −44.5% price move — the price outran earnings, pushing the multiple UP its own range.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Gem Aromatics Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 5 quarters across 1 curve, on partial evidence.

Growth, year by year: revenue −27.4% in FY26, profit −98.1% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
40%57%22%15%4.0%−26%−14%−68%−32%−110%%%−27.4%−98.1%FY21FY23FY26
40%57%22%15%4.0%−26%−14%−68%−32%−110%%%−27.4%−98.1%FY21FY23FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Where the trailing-twelve-month history is short, the curve falls back to single-quarter year-on-year growth — noisier, and the classifier smooths and caps base-effect spikes before reading. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from
RevenueProfitEPS
17%8.2%0.0%−47%−16%−103%−33%−158%−50%−214%%%12.8%−198.6%−124.6%Jun 24Jun 25Jun 26
17%8.2%0.0%−47%−16%−103%−33%−158%−50%−214%%%12.8%−198.6%−124.6%Jun 24Jun 25Jun 26
ROCE Annual readings — the quarterly balance-sheet pieces this curve needs are not held for this stock, so the returns read moves once a year and carries less weight in the call.
the return curve, annual readings
ROCE
27%20%14%7.6%1.2%%3%FY23FY24FY26
27%20%14%7.6%1.2%%3%FY23FY24FY26
ROCE
Falling
latest 3.0% · span 3.0%–25.0%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue−27.4%−4.9%+3.6%
Profit−98.1%−71.9%−46.6%
EPS−97.6%−89.7%−70.9%
Share price−44.5%
Revenue YoY (Jun 26)
+12.8%
latest quarter vs a year ago
Profit YoY (Jun 26)
−198.6%
latest quarter vs a year ago
Revenue 10y
3.6%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

24.4/100 — rank 18 of 20 in Chemicals - Organic · 65% evidence confidence

Gem Aromatics Ltd scores 24.4 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 18. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 1.8 + 6.4 + 8.5 + 7.7 = 24.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Gem Aromatics Ltd reported ₹98.8 Cr of revenue in the Jun 26 quarter, +12.8% year on year. Over 5 years it has compounded at 3.6% a year. The last full year, FY26, came in at ₹366 Cr. The last four reported quarters add to ₹378 Cr.

FY26 revenue came in at ₹366 Cr (−27.4% on the year), capping 5 years at 3.6% compound. The latest quarter (Jun 26) printed ₹98.8 Cr, +12.8% year on year.

FY26 revenue ₹366 Cr (−27.4% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 6-year window. A bar is red when it is lower than the year before.
3.6% a year over 5 years
RevenueYoY growth
54440%40822%2724.0%136−14%0−32%₹ Cr%₹366−27.4%FY21FY23FY26
54440%40822%2724.0%136−14%0−32%₹ Cr%₹366−27.4%FY21FY23FY26
Jun 26: ₹98.8 Cr (+12.8% YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
21817%1640.0%109−16%55−33%0−50%₹ Cr%₹9912.8%Jun 24Jun 25Jun 26
21817%1640.0%109−16%55−33%0−50%₹ Cr%₹9912.8%Jun 24Jun 25Jun 26

Pace check: the last four quarters averaged −17.8% growth against the decade's 3.6% — the current year is running slower than its own long-run rate.

06 · Operating margin

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Gem Aromatics Ltd's operating margin is 3.3% in the Jun 26 quarter, −13.6 percentage points against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged 10.0% to 18.0%. The current quarter is running below every full year in that window.

The latest quarter's operating margin is 3.3%, −13.6 pp against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged 10.0%–18.0%.

🚨 Why the margin moved: operating margin went −13.6 pp year on year while gross margin went −12.8 pp — the loss came mostly from the gross line: input costs and pricing.

FY26: 11.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 6-year window.
within a 10.0–18.0% band over 6 years
operating marginYoY change (pp)
19%7.0%16%3.3%14%−0.5%12%−4.3%9.4%−8.0%%%11%−7%FY21FY23FY26
19%7.0%16%3.3%14%−0.5%12%−4.3%9.4%−8.0%%%11%−7%FY21FY23FY26
Jun 26: 3.3% operating margin (−13.6 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
24%2.8%19%−1.6%13%−6.0%7.4%−10%1.8%−15%%%3.3%−13.6%Jun 24Jun 25Jun 26
24%2.8%19%−1.6%13%−6.0%7.4%−10%1.8%−15%%%3.3%−13.6%Jun 24Jun 25Jun 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Gem Aromatics Ltd posted a net loss of ₹7.9 Cr in the Jun 26 quarter. Full-year FY26 profit was ₹1.0 Cr. The 5-year compound rate is −46.6%. That loss is 8.0% of the quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr. 3 of the last 9 reported quarters were loss-making.

Jun 26 profit was ₹−7.9 Cr, −198.6% year on year. On the full year, FY26 printed ₹1.0 Cr (−98.1%), and the 5-year compound rate is −46.6%.

FY26 profit ₹1.0 Cr (−98.1% YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 6-year window. A bar is red when it is lower than the year before.
−46.6% a year over 5 years
Net profitYoY growth
5757%4315%29−26%14−68%0−110%₹ Cr%₹1−98.1%FY21FY23FY26
5757%4315%29−26%14−68%0−110%₹ Cr%₹1−98.1%FY21FY23FY26
Jun 26: ₹−7.9 Cr (−198.6% YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
308.2%20−47%10−103%0−158%−11−214%₹ Cr%₹−8−198.6%Jun 24Jun 25Jun 26
308.2%20−47%10−103%0−158%−11−214%₹ Cr%₹−8−198.6%Jun 24Jun 25Jun 26

🚨 Why profit moved: revenue contributed +12.8% and the margin −13.6 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit −147.1% vs revenue −17.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 43% of Gem Aromatics Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹30.0 Cr of operating cash against ₹1.0 Cr of profit. After ₹102 Cr of capital spending, ₹−72.0 Cr was left as free cash.

FY26: operating cash of ₹30.0 Cr against reported profit of ₹1.0 Cr, leaving free cash of ₹−72.0 Cr after ₹102 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 43% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY26: CFO ₹30.0 Cr vs profit ₹1.0 Cr Operating cash flow and net profit by fiscal year, ₹ Cr; the line is free cash flow (CFO minus capital spending). 6-year window, annual resolution.
43% of 3-year profit arrived as cash
Operating cashNet profitFree cash
6814−40−93−147₹ Cr₹30₹1₹−72FY21FY23FY26
6814−40−93−147₹ Cr₹30₹1₹−72FY21FY23FY26
FY26: CFO = 3,000% of profit (three-year rate 43%) Operating cash as a share of net profit, per fiscal year, % (line). Dashed line = 100% — every unit of profit arriving as cash; outlier years shown pinned.
Conversion100%
328%227%127%26%−75%%300%FY21FY23FY26
328%227%127%26%−75%%300%FY21FY23FY26

🚨 Why conversion sits at 43%: the cash cycle stretched 200 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 200 days — the next section's job is to find where the cash is stuck.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Gem Aromatics Ltd's cash conversion cycle runs 360 days in FY26, up from 160 days in FY21. Capital spending ran ₹248 Cr over the last 3 years. At FY26 sales of ₹366 Cr each day of that cycle holds about ₹1.0 Cr, so roughly ₹361 Cr sits inside the business at any moment.

FY26: debtors at 76 days, inventory at 309 days — roughly 10.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 360 days, looser than FY21's 160.

The full loop: cash goes out to suppliers and production on day 0; stock waits 309 days to sell; customers pay about 76 days after that; and suppliers themselves are paid at 25 days — netting out to the 360-day cycle.

In money terms: at FY26 sales of ₹366 Cr, each day of the cycle holds about ₹1.0 Cr — so the 360-day loop keeps roughly ₹361 Cr sitting inside the business at any moment.

FY26: a 360-day cash cycle Debtor days, inventory days, payable days and the cash conversion cycle by fiscal year. 6-year window.
+200 days vs FY21
Cash cycleInventory daysDebtor daysPayable days
38828818888−12days360d309d76d25dFY21FY22FY23FY24FY26
38828818888−12days360d309d76d25dFY21FY23FY26

On the investment side: capital spending of ₹248 Cr over the last 3 fiscal years against ₹36.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹6.0 Cr (FY26) — capacity paid for but not yet earning.

FY26: capex ₹102 Cr, work-in-progress ₹6.0 Cr Capital spending per fiscal year, ₹ Cr (bars); capital work-in-progress, ₹ Cr (line). Quarterly capital-spending history is not held for India — annual is the honest resolution.
a build-out
CapexWork-in-progress
13610268340₹ Cr₹102₹6FY22FY23FY24FY25FY26
13610268340₹ Cr₹102₹6FY22FY24FY26

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

10 · Return on capital

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Gem Aromatics Ltd earns a ROCE of 3% in FY26. Return on invested capital clears the cost of that capital by −11.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 0.3% net margin on 0.57× asset turns.

FY26 ROCE is 3%.

🚨 Why the return is what it is — the wiring (FY26): 0.3% net margin × 0.57× asset turns × 1.43× balance-sheet leverage ≈ 0.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 0.7% − 12.0% = a −11.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY26: ROCE 3% Return on capital employed by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 12.0% cost of capital used on this page.
the full ladder
ROCEROIC (annual)WACC
27%20%13%5.8%−1.2%%3%0.7%FY22FY24FY26
27%20%13%5.8%−1.2%%3%0.7%FY22FY24FY26
Q4 FY26: ROCE 3.8% (TTM) vs WACC 12.0% Trailing-twelve-month ROCE and ROIC, per quarter, %; dashed line = the cost of capital. Last 6 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROCE (TTM)ROIC (TTM)WACC
25%18%11%4.6%−2.2%%3.8%−0.3%Q2 FY25Q4 FY25Q4 FY26
25%18%11%4.6%−2.2%%3.8%−0.3%Q2 FY25Q4 FY25Q4 FY26
11 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Gem Aromatics Ltd carries total debt of ₹152 Cr against shareholder equity of ₹450 Cr as of Mar 26, a debt-to-equity of 0.34. On the annual view that ratio went from 0.79 in FY25 to 0.34 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹152 Cr against shareholder equity of ₹450 Cr — a debt-to-equity of 0.34. On the annual view, debt-to-equity went from 0.79 (FY25) to 0.34 (FY26). Read the returns on this page with that leverage in mind.

FY26: debt ₹152 Cr at 0.34× equity Total debt by fiscal year, ₹ Cr (bars); debt-to-equity, × (line). 2-year window.
Total debtDebt-to-equity
2430.8×1820.7×1220.6×610.4×00.3×₹ Cr×₹1520.34×FY25FY26
2430.8×1820.7×1220.6×610.4×00.3×₹ Cr×₹1520.34×FY25FY26
Mar 26: debt ₹152 Cr, debt-to-equity 0.34 Total debt per quarter, ₹ Cr (bars); debt-to-equity, × (line). Last 7 quarters. India reports the full balance sheet half-yearly, so the intervening quarter carries the prior reading forward.
Total debt (quarterly)Debt-to-equity
2430.8×1820.7×1220.6×610.4×00.3×₹ Cr×₹1520.34×Jun 24Jun 25Mar 26
2430.8×1820.7×1220.6×610.4×00.3×₹ Cr×₹1520.34×Jun 24Jun 25Mar 26
12 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Gem Aromatics Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — .

A quiet register: no holder moved a full point in two years Shareholding by holder class, % of the company, quarterly, last 4 quarters.
PromotersForeign inst.Domestic inst.Public
62%46%29%13%−3.8%%57.4%0.8%4.8%37%Sep 25Dec 25Jun 26
62%46%29%13%−3.8%%57.4%0.8%4.8%37%Sep 25Dec 25Jun 26
13 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Gem Aromatics Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

14 · Related companies · Chemicals - Organic
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Valiant Organics LtdVALIANTORG 63.2/100Mixed-positive evidence87% evidence TURNING 24.4/35 Revenue 1.5% · PAT 100% · OPM change 6 pp 95% evidence 10.8/25 ROCE 5.5% · OPM 18% 95% evidence 11.0/20 P/E 22× · PEG — 50% evidence 17.0/20 RS sector 9.4% · RS bench 42.8% · 1Y 9.4%5 of 12 weeks ahead 100% evidence
Exact sum: 24.4 + 10.8 + 11 + 17 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Foseco India LtdFOSECOIND 63.1/100Mixed-positive evidence87% evidence BREAKING OUT 19.5/35 Revenue 32.6% · PAT 20.5% · OPM change 5.2 pp 100% evidence 16.9/25 ROCE 17.4% · OPM 23% 100% evidence 11.5/20 P/E 44.8× · PEG 1.31 65% evidence 15.2/20 RS sector 24.1% · RS bench 21% · 1Y -4%6 of 10 weeks ahead 70% evidence
Exact sum: 19.5 + 16.9 + 11.5 + 15.2 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Elantas Beck India LtdELANTAS 62.3/100Mixed-positive evidence76% evidence BREAKING OUT 26.3/35 Revenue 17.6% · PAT 33.1% · OPM change 10 pp 95% evidence 19.1/25 ROCE 21.2% · OPM 29% 76% evidence 6.3/20 P/E 64.8× · PEG — 50% evidence 10.6/20 RS sector -6.6% · RS bench 52.4% · 1Y 35.2%6 of 9 weeks ahead 70% evidence
Exact sum: 26.3 + 19.1 + 6.3 + 10.6 = 62.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
4OCCL LtdOCCLLTD 61.4/100Mixed-positive evidence60% evidence BREAKING OUT 26.5/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence 12.2/25 ROCE 13% · OPM 28% 76% evidence 11.5/20 P/E 10.4× · PEG — 15% evidence 11.2/20 RS sector — · RS bench 41.5% · 1Y —9 of 9 weeks ahead 25% evidence
Exact sum: 26.5 + 12.2 + 11.5 + 11.2 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Shri Ahimsa Naturals LtdSHRIAHIMSA 61.0/100Thin evidence · provisional56% evidence LEADER 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence 18.0/25 ROCE 21.7% · OPM 28% 95% evidence 10.0/20 P/E 37.2× · PEG — 15% evidence 14.1/20 RS sector 22.9% · RS bench 58.3% · 1Y 113%12 of 12 weeks ahead 100% evidence
Exact sum: 18.9 + 18 + 10 + 14.1 = 61 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
6Indo Amines LtdINDOAMIN 60.6/100Mixed-positive evidence81% evidence BASING 22.3/35 Revenue 13.3% · PAT 24.2% · OPM change 3 pp 95% evidence 16.8/25 ROCE 19.9% · OPM 14% 95% evidence 14.0/20 P/E 11.3× · PEG — 50% evidence 7.5/20 RS sector -11.9% · RS bench 4.6% · 1Y -12.6%4 of 10 weeks ahead 70% evidence
Exact sum: 22.3 + 16.8 + 14 + 7.5 = 60.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Balaji Amines LtdBALAMINES 59.3/100Mixed-positive evidence82% evidence LEADER 26.4/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence 13.3/25 ROCE 11% · OPM 25% 76% evidence 7.0/20 P/E 36.1× · PEG — 50% evidence 12.6/20 RS sector 18.3% · RS bench 51.3% · 1Y 53.1%12 of 12 weeks ahead 100% evidence
Exact sum: 26.4 + 13.3 + 7 + 12.6 = 59.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Nitta Gelatin India LtdNITTAGELA 59.2/100Mixed-positive evidence72% evidence TURNING 18.8/35 Revenue 10.5% · PAT 24.1% · OPM change 4 pp 95% evidence 19.1/25 ROCE 27.7% · OPM 24% 95% evidence 9.7/20 P/E 14.4× · PEG — 50% evidence 11.6/20 RS sector — · RS bench 46.7% · 1Y —7 of 9 weeks ahead 25% evidence
Exact sum: 18.8 + 19.1 + 9.7 + 11.6 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9BASF India LtdBASF 52.7/100Mixed-positive evidence94% evidence BREAKING OUT 20.0/35 Revenue 6.5% · PAT 62.4% · OPM change 4 pp 100% evidence 10.7/25 ROCE 14.5% · OPM 10% 100% evidence 14.3/20 P/E 25.7× · PEG 1.62 100% evidence 7.7/20 RS sector -3.3% · RS bench -3.4% · 1Y -21.2%4 of 11 weeks ahead 70% evidence
Exact sum: 20 + 10.7 + 14.3 + 7.7 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10GFL LtdGFLLIMITED 51.5/100Mixed-positive evidence72% evidence BREAKING OUT 23.9/35 Revenue 10.5% · PAT 100% · OPM change 1064 pp 71% evidence 7.8/25 ROCE 2.1% · OPM 28.2% 95% evidence 11.3/20 P/E 10.6× · PEG — 15% evidence 8.5/20 RS sector -14% · RS bench 12.9% · 1Y -2.6%7 of 12 weeks ahead 100% evidence
Exact sum: 23.9 + 7.8 + 11.3 + 8.5 = 51.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Laxmi Organic Industries LtdLXCHEM 49.5/100Mixed-negative evidence94% evidence BREAKING OUT 19.9/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence 8.4/25 ROCE 4.7% · OPM 12% 100% evidence 14.7/20 P/E 38.8× · PEG 1.14 100% evidence 6.5/20 RS sector -19.5% · RS bench 9.7% · 1Y -16.6%9 of 10 weeks ahead 70% evidence
Exact sum: 19.9 + 8.4 + 14.7 + 6.5 = 49.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Fine Organic Industries LtdFINEORG 45.6/100Mixed-negative evidence100% evidence BREAKING OUT 14.8/35 Revenue 7.1% · PAT 5.8% · OPM change 4 pp 100% evidence 17.6/25 ROCE 21.5% · OPM 25% 100% evidence 7.2/20 P/E 36.2× · PEG 2.7 100% evidence 6.0/20 RS sector -13.8% · RS bench 12.9% · 1Y 7.1%9 of 12 weeks ahead 100% evidence
Exact sum: 14.8 + 17.6 + 7.2 + 6 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13Jyoti Resins and Adhesives LtdJYOTIRES 43.1/100Mixed-negative evidence69% evidence 9.7/35 Revenue 12.8% · PAT -11.1% · OPM change -13 pp 95% evidence 19.2/25 ROCE 36.5% · OPM 14% 76% evidence 10.8/20 P/E 16.2× · PEG — 15% evidence 3.4/20 RS sector -19.8% · RS bench -11.8% · 1Y -31.4%0 of 12 weeks ahead 70% evidence
Exact sum: 9.7 + 19.2 + 10.8 + 3.4 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Sigachi Industries LtdSIGACHI 41.5/100Mixed-negative evidence79% evidence BREAKING OUT 9.0/35 Revenue -9.6% · PAT 100% · OPM change -5.2 pp 71% evidence 7.2/25 ROCE 6.2% · OPM 13.6% 95% evidence 8.4/20 P/E 64.5× · PEG — 50% evidence 16.9/20 RS sector 6.2% · RS bench 38.7% · 1Y 20.6%11 of 12 weeks ahead 100% evidence
Exact sum: 9 + 7.2 + 8.4 + 16.9 = 41.5 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
15Shree Ganesh Remedies LtdSGRL 41.1/100Mixed-negative evidence76% evidence 6.6/35 Revenue -8.8% · PAT -29.4% · OPM change -6.3 pp 95% evidence 14.6/25 ROCE 14.1% · OPM 23.3% 76% evidence 7.1/20 P/E 54.8× · PEG — 50% evidence 12.8/20 RS sector 3.3% · RS bench 25.3% · 1Y 15.5%4 of 12 weeks ahead 70% evidence
Exact sum: 6.6 + 14.6 + 7.1 + 12.8 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Oriental Aromatics LtdOAL 36.0/100Mixed-negative evidence74% evidence BREAKING OUT 12.5/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence 4.3/25 ROCE 4.5% · OPM 7.6% 95% evidence 8.7/20 P/E 337× · PEG — 15% evidence 10.5/20 RS sector -8.7% · RS bench 66.9% · 1Y 57.7%10 of 10 weeks ahead 70% evidence
Exact sum: 12.5 + 4.3 + 8.7 + 10.5 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Fairchem Organics LtdFAIRCHEMOR 33.6/100Adverse evidence87% evidence BREAKING OUT 17.1/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence 6.0/25 ROCE 3.3% · OPM 10% 95% evidence 8.0/20 P/E 52× · PEG — 50% evidence 2.5/20 RS sector -26.6% · RS bench -3.9% · 1Y -22.2%11 of 12 weeks ahead 100% evidence
Exact sum: 17.1 + 6 + 8 + 2.5 = 33.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Gem Aromatics Ltdthis pageGEMAROMA 24.4/100Adverse evidence65% evidence ASLEEP 1.8/35 Revenue -24.3% · PAT -80% · OPM change -13.6 pp 95% evidence 6.4/25 ROCE 3.4% · OPM 3.3% 95% evidence 8.5/20 P/E 772.2× · PEG — 15% evidence 7.7/20 RS sector — · RS bench -10.4% · 1Y -39.3%5 of 10 weeks ahead 25% evidence
Exact sum: 1.8 + 6.4 + 8.5 + 7.7 = 24.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Sacheerome LtdSACHEEROME 59.1/100Thin evidence · provisional41% evidence BREAKING OUT 17.3/35 Revenue — · PAT — · OPM change 1 pp 26% evidence 20.3/25 ROCE 35.7% · OPM 23% 95% evidence 9.7/20 P/E 40.1× · PEG — 15% evidence 11.8/20 RS sector — · RS bench 46.9% · 1Y 155.5%9 of 10 weeks ahead 25% evidence
Exact sum: 17.3 + 20.3 + 9.7 + 11.8 = 59.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
20Citurgia Biochemicals LtdCITURGIA 36.7/100Thin evidence · provisional27% evidence 11.8/35 Revenue — · PAT -68.2% · OPM change — 33% evidence 4.9/25 ROCE -2150% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence
Exact sum: 11.8 + 4.9 + 10 + 10 = 36.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

15 · Frequently asked questions

Frequently asked questions

What is Gem Aromatics Ltd's share price today?

Gem Aromatics Ltd trades at ₹161, −44.5% over the past year. The company is valued at ₹840 Cr. The stock sits at 18% of its 52-week range of ₹141–₹252, −14.3% versus its 200-day average. On the tape, the price is in a downtrend, 55 weeks in. — as of 11 September 2026.

What were Gem Aromatics Ltd's latest quarterly results?

Gem Aromatics Ltd reported revenue of ₹98.8 Cr and a net loss of ₹7.9 Cr for the Jun 26 quarter. Revenue rose 12.8% and profit fell 198.6% year on year. Earnings per share were ₹−1.51. The operating margin was 3.3%, 13.6 pp lower than a year earlier. — as of 11 September 2026.

What is Gem Aromatics Ltd's revenue?

Gem Aromatics Ltd reported revenue of ₹98.8 Cr in the Jun 26 quarter, +12.8% year on year. For the full FY26 fiscal year, revenue was ₹366 Cr (−27.4%). Over the last 5 years revenue compounded at 3.6% a year. — as of 11 September 2026.

What is Gem Aromatics Ltd's profit?

Gem Aromatics Ltd earned ₹−7.9 Cr of net profit in the Jun 26 quarter, −198.6% year on year. Full-year FY26 profit was ₹1.0 Cr. The operating margin ran 3.3% in the latest quarter. — as of 11 September 2026.

What is Gem Aromatics Ltd's market cap?

Gem Aromatics Ltd's market capitalisation is ₹840 Cr at a share price of ₹161. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.

What is Gem Aromatics Ltd's P/E ratio?

Gem Aromatics Ltd trades at a P/E of 25.8×, at the 65th percentile of its own 1-year range, against a long-run median of 23.9×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.

Does Gem Aromatics Ltd pay a dividend?

No — Gem Aromatics Ltd has recorded a dividend payout of 0% of profit in each of its last 6 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 11 September 2026.

Is Gem Aromatics Ltd overvalued?

On its own history, Gem Aromatics Ltd looks expensive: its P/E of 25.8× sits at the 65th percentile of its 1-year range (long-run median 23.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.

Is Gem Aromatics Ltd growing?

Not right now — Gem Aromatics Ltd's latest numbers are shrinking: latest-quarter revenue +12.8% year on year, profit −198.6%, and the margin −13.6 pp at 3.3%. The 5-year compound rates are 3.6% (revenue) and −46.6% (profit). The earnings engine currently reads: deteriorating — as of 11 September 2026.

How is Gem Aromatics Ltd performing?

Gem Aromatics Ltd is in a downtrend, 55 weeks in. Its latest quarter's revenue rose 12.8% and profit fell 198.6% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 11 September 2026.

Is Gem Aromatics Ltd in an uptrend?

No — the price is in a downtrend (week 55 of stage 4), trading −14.3% versus its 200-day average and at 18% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.

Is Gem Aromatics Ltd beating the market?

Not lately — on a trailing-13-week view Gem Aromatics Ltd is currently behind the NIFTY 500 (5 weeks and counting; last ahead the week of 2026-08-07), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.0 years the stock moved −42% against the NIFTY 500's +0% — behind the index over the full window. — as of 11 September 2026.

Will Gem Aromatics Ltd's share price go up?

This page publishes no price forecast for Gem Aromatics Ltd. What it measures instead: the share price is ₹161, the price is in a downtrend 55 weeks in. Its P/E of 25.8× sits at the 65th percentile of its own 1-year range. — as of 11 September 2026.

Who owns Gem Aromatics Ltd?

Promoters hold 57.4% of Gem Aromatics Ltd, foreign institutions 0.8%, domestic institutions 4.8% and the public 37.0% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.

Does Gem Aromatics Ltd have too much debt?

It is moderate — Gem Aromatics Ltd's debt-to-equity is 0.34, and operating profit covers the interest bill 3×. FY26 borrowings were ₹152 Cr against equity of ₹449 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.

What is Gem Aromatics Ltd's capex?

Gem Aromatics Ltd spent ₹248 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹102 Cr, with ₹6.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.

What is Gem Aromatics Ltd's cash flow?

Gem Aromatics Ltd generated ₹30.0 Cr of operating cash flow in FY26 and ₹−72.0 Cr of free cash flow after ₹102 Cr of capital spending. Reported profit that year was ₹1.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.

Is Gem Aromatics Ltd's profit real cash?

Not fully — over the last 3 fiscal years, 43% of Gem Aromatics Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹30.0 Cr against reported profit of ₹1.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 11 September 2026.

Where is Gem Aromatics Ltd in its business cycle?

Gem Aromatics Ltd's FY26 operating margin was 11.0%, against a 6-year band of 10.0%–18.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 3.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.

What could break the Gem Aromatics Ltd story?

The sharpest disagreement: the price moved −44.5% in a year while annual EPS moved −97.6% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.

Is Gem Aromatics Ltd a stock worth studying right now?

This is not investment advice. The machine read: Gem Aromatics Ltd's price has outrun its earnings. −44.5% in a year against EPS −97.6% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-11. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI